valproic acid has been researched along with Focal Segmental Glomerulosclerosis in 4 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study we compared the effect of two HDAC inhibitors, trichostatin A and valproic acid, in an experimental model of kidney fibrosis." | 7.79 | Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. ( Geers, C; Mannaerts, I; Pauwels, M; Van Beneden, K; Van den Branden, C; van Grunsven, LA; Wissing, KM, 2013) |
| " In this study we compared the effect of two HDAC inhibitors, trichostatin A and valproic acid, in an experimental model of kidney fibrosis." | 3.79 | Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis. ( Geers, C; Mannaerts, I; Pauwels, M; Van Beneden, K; Van den Branden, C; van Grunsven, LA; Wissing, KM, 2013) |
| "Valproic acid was proved to be effective in reducing the number of attacks over 4 months." | 1.30 | Periodic discharge of adrenocorticotropin and vasopressin associated with focal glomerulosclerosis. ( Fujieda, M; Kurashige, T; Machida, Y; Maeda, A; Maeda, H; Naruse, K; Okada, T; Ushida, M; Wakiguchi, H; Yokoyama, W, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Van Beneden, K | 2 |
| Geers, C | 2 |
| Pauwels, M | 2 |
| Mannaerts, I | 2 |
| Wissing, KM | 1 |
| Van den Branden, C | 2 |
| van Grunsven, LA | 2 |
| Verbeelen, D | 1 |
| Ackoundou-N'guessan, C | 1 |
| Canaud, B | 1 |
| Leray-Moragues, H | 1 |
| Droz, D | 1 |
| Baldet, P | 1 |
| Pages, M | 1 |
| Yokoyama, W | 1 |
| Fujieda, M | 1 |
| Okada, T | 1 |
| Maeda, H | 1 |
| Ushida, M | 1 |
| Machida, Y | 1 |
| Naruse, K | 1 |
| Maeda, A | 1 |
| Wakiguchi, H | 1 |
| Kurashige, T | 1 |
4 other studies available for valproic acid and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis.
Topics: Acetylation; Animals; Doxorubicin; Female; Fibrosis; Glomerulosclerosis, Focal Segmental; Histone De | 2013 |
Valproic acid attenuates proteinuria and kidney injury.
Topics: Acute Kidney Injury; Animals; Antibiotics, Antineoplastic; Disease Models, Animal; Doxorubicin; Drug | 2011 |
Collapsing focal segmental glomerulosclerosis as a possible complication of valproic acid.
Topics: Adult; Anticonvulsants; Drug Administration Schedule; Glomerulosclerosis, Focal Segmental; Humans; M | 2007 |
Periodic discharge of adrenocorticotropin and vasopressin associated with focal glomerulosclerosis.
Topics: Adrenocorticotropic Hormone; Child; Glomerulosclerosis, Focal Segmental; Humans; Kidney Failure, Chr | 1998 |